Gritstone bio (GRTS) Set to Announce Earnings on Thursday

Gritstone bio (NASDAQ:GRTS) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Gritstone bio (NASDAQ:GRTS) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. The company had revenue of $10.38 million for the quarter, compared to analyst estimates of $4.80 million. Gritstone bio had a negative return on equity of 147.22% and a negative net margin of 847.24%. On average, analysts expect Gritstone bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gritstone bio Price Performance

NASDAQ:GRTS traded up $0.06 during mid-day trading on Tuesday, reaching $1.02. 872,308 shares of the stock were exchanged, compared to its average volume of 2,718,026. The business has a fifty day moving average price of $1.70 and a 200 day moving average price of $1.89. Gritstone bio has a 1-year low of $0.67 and a 1-year high of $3.33. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.20 and a quick ratio of 3.20.

Wall Street Analyst Weigh In

Several research firms have issued reports on GRTS. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Gritstone bio in a report on Wednesday, March 6th. JMP Securities lifted their target price on Gritstone bio from $4.00 to $5.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 2nd.

Gritstone bio Company Profile

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.